The FDA is poised to issue a final decision on the approval and marketing of Yutrepia, an inhaled dry powder formulation of ...

United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

Good morning and welcome everyone to the Liquidia Corporation full year 2024 financial result and corporate update conference call. My name is Shannon, and I will be your conference operator today.

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

To date, participants have safely titrated to the study’s maximum dose twice daily, which is comparable to 26-28 breaths of Tyvaso® administered four times per day. The FDA has confirmed that a single ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against ...